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Nimodipine (NMD) is a dihydropyridine calcium channel blocker with selectivity for ce-
rebral blood vessels and the major therapeutic indication of NMD is for the prevention and
treatment of delayed ischemic neurological disorders and other cerebrovascular disorders,
such as stroke which is associated with biological rhythm. This study was mainly designed
to solve the drawback of conventional NMD solid dosage form, low bioavailability and
limited clinical efficacy, by preparing enteric solid dispersion (SD) and the SD was prepared
via melting method. The physical state of the dispersed NMD in the polymer matrix was
characterized by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD)
and dissolution studies. Compared with pure drug and physical mixture, the dissolution of
NMD-SD was enhanced dramatically (about 80%). Furthermore, in consideration of the
biological rhythm of stroke, we first obtained a delayed-release tablet containing NMD-SD
by a direct powder compression method. As shown in the dissolution studies, the tablet
released less than 10% in the artificial gastric acid in the initial 2 h and released 32.1%, 75%,
more than 90% at 4, 10 and 14 h respectively in the artificial intestinal fluid. This investi-
gation has solved the problems of oral solid dosage forms of NMD, and it has the good
industry prospect.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
A poorly water-soluble drug often shows insufficient
bioavailability due to its poor solubility and low dissolution
rate after administration, especially for class II substances86313.
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enhancing its specific surface area or solubility can be take
into consideration, such as micronization, enhancing the
wettability and solid dispersion technology.
SD technology is an available method which can affect
both specific surface area and solubility. It makes compounds
disperse in carriers or matrixes at solid state and has been
widely used in both pre-clinical and clinical formulation
development as a successful approach to deliver insoluble
compounds [1]. There are many alternatives for the manu-
facture of SD, such as melting (fusion), melting-solvent, hot-
melt extrusion (HME), spray drying, co-evaporation and
freeze-drying. Although SD technique has been extensively
confirmed to enhance the dissolution characteristics of the
sparingly soluble drugs, the practical applicability of the sys-
tem has remained limited mainly due to the difficulties in
manufacturing process, such as poor reproducibility of phys-
icochemical properties, the complexity of dosage form
development and less feasibility for scale up of industrializa-
tion. Besides, those carriers, frequently used in solid disper-
sion, also cause problems of aging due to their hygroscopic
nature [2]. Therefore, more attempts about searching new
carriers or innovative techniques are needed, and they are
especially significant for large-scale manufacturing. In this
work, a new excipient, hypromellose acetate succinate
(HPMCAS), has been explored to serve for SD carrier material,
and co-evaporation and melting were chosen as the fabrica-
tion methods.
HPMCAS is usually employed as an enteric coating mate-
rial for enteric or sustained release formulations. But recently,
it is also a polymer which can be applied in SD technology as a
new carrier or matrix for poorly water-soluble drugs to in-
crease both dissolution rate and solubility. According to
different contents of acetyl and succinoyl groups in the poly-
mer, there are three kinds of HPMCAS on themarket, i.e. AS-L,
AS-M and AS-H. Type L has a low ratio (0.53) of acetyl sub-
stitution to succinoyl substitution (A/S ratio), while typeMhas
a medium A/S ratio (0.81), and a high A/S ratio (2.00) is type H.
These three types of excipients dissolve at different levels of
pH which increase with A/S ratios: Type L dissolves in a me-
dium of pH 5.5 or higher; type M dissolves at pH 6.0 or higher;
type H dissolves at pH no less than 6.8. Besides, every type of
HPMCAS is available in fine (mean particle size: 5 mm) and
granular particle (mean particle size: 1 mm) [3].
In this investigation, we selected nimodipine, a drug be-
longs to BCS II, as the model drug. Nimodipine (NMD) is a
dihydropyridine calcium channel blocker with selectivity for
cerebral blood vessels and the major therapeutic indication of
NMD is for the prevention and treatment of delayed ischemic
neurological disorders and other cerebrovascular disorders,
such as stroke which is indicated to have biological rhythm
[4]. Biological rhythm may affect normal biological functions
such as heart rate, blood pressure, body temperature, blood-
plasma concentration and platelet aggregation [5]. The
symptoms of many diseases have followed the body’s bio-
logical rhythm. The attacks and symptoms of illness like
asthma attacks, coronary infarction, angina pectoris, stroke,
and ventricular tachycardia are circadian-phase dependent
[6]. A few researches have been carried on to provide strong
evidence that stroke has a higher risk in the early morning h(03:00 a.m. to 06:00 a.m.) and lower risk during the night time
period (21:00 p.m. to midnight). It meant that NMD prepara-
tion should be modified to achieve an efficient drug level at an
optimum time, improving disease therapy, rather thanmerely
maintaining constant drug concentrations. In one word, bio-
logical rhythms may be applied to pharmacotherapy by
adopting a dosage form that synchronizes drug concentra-
tions to rhythms in disease activity [7e9].
Oral administration of conventional solid dosage form of
NMD is associated with certain problems such as frequent
dosing (30e60 mg every 4e8 h), varying half-life, fluctuating
plasma concentrations, lower bioavailability and limited
clinical efficacy,mainly due to the lowwater solubility of NMD
[10]. In view of chronopharmacology in disease treatment, and
that the improvement of NMD dissolution rate is a solution to
the problems of lower bioavailability and limited clinical ef-
ficacy, the objective of this investigation is to prepare a
delayed-release tablet, containing NMD enteric SD which can
effectively increase the dissolution rate and reduce dosing
frequency. Because the delayed-release function of NMD can
be realized via the enteric character of SD, the coating process
is omitted for simplifying the process. Because there is a lower
risk of stroke during the night time period (21:00 p.m. to
midnight), and in view of 2 h’ retention time in stomach, the
patients can take the medicine at 22:00 p.m. The release pro-
file of the delayed-release tablet will be prolonged, as starting
to release at 24:00, and cover the high-incidence period of
stroke. In addition, all experiments were carried out in a dark
room in view of the sensitivity of nimodipine to light.2. Materials and methods
2.1. Materials
Nimodipine (NMD) was obtained from Zhengzhou Ruikang
Pharmaceutical Company (Zhengzhou, Henan, China).
Hypromellose acetate succinate (HPMCAS) and Hypromellose
Phthalate (HPMCP) was purchased from Shin-Etsu Chemical
Co., Ltd. (Japan). Polyvinylacetat-Polyvinylpyrrolidon
(Kollidon SR) was supplied by Trademark BASF. Microcrys-
talline Cellulose (MCC) was obtained from Asahi Kasei
Chemicals Corporation (Japan). Eudragit RS PO was pur-
chased from Degussa (China) Co., Ltd. Polyethylene oxide
(PEO, N-12K) was supplied by The Dow Chemical Company
(Shanghai, China).
2.2. Preparation of solid dispersion containing
nimodipine (NMD-SD)
Co-evaporation and melting methods are the two major op-
tions of preparing solid dispersion. Through the preliminary
experiments, we selected the melting method other than co-
evaporation method, because the melting procedure seemed
to be more convenient and it involved with no organic solvent
during preparation process, which ensured a cost-effective
method of production.
All the excipients and drug were firstly screened through
100-mesh sieve and mixed uniformly to obtain the physical
mixture, then melted the physical mixture with stir, followed
Table 2 e Formulations of NMD delayed-release tablets.
No. Kollidon
SR (mg)
MCC
(mg)
Eudragit
RS PO (mg)
PEO
(mg)
Formulation 1 40 60 e 80
Formulation 2 40 e 60 80
Formulation 3 40 20 20 80
Formulation 4 100 e e 80
Formulation 5 80 100 e e
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last step, the SD powder was screened through 100-mesh
sieve. In Table 1, from SD0 to SD5, six types of HPMCAS were
respectively used to prepare solid dispersions with the con-
dition that the ratio of HPMCAS to NMD is 3:1. To investigate
whether the combined carriers were better than the single
carrier for improving dissolution of poorly water-soluble drug,
we had chosen HP-55, HPMCAS as the combined carriers and
HPMCAS as the single carrier. The formulations were sum-
marized in Table 1 (SD6 and SD11). A further study for con-
firming the optimal ratio of NMD to carrier with the selected
type of HPMCAS was also performed, and the relative for-
mulations, from SD7 to SD11, were listed in Table 1.2.3. Preparation of delayed-release tablets
Here, a delayed-release tablet means the enteric tablet, an
enteric tablet should meet the characteristic that the drug
doesn’t release or scarcely release in the gastric fluid and re-
leases completely in the intestinal fluid. Accurate amount of
solid dispersion containing 60mg of NMD, a certain amount of
Kollidon SR, Microcrystalline Cellulose (MCC), Eudragit RS
PO or Polyethylene oxide (PEO) were weighed and mixed
together. The formulations are summarized in Table 2. A
single-punch press (TDP-5, Shanghai Tianfan Pharmaceutical
Machine Factory, Shanghai, China) equipped with a 10 mm
diameter concave-faced punch and die set was used in the
process of compressing tablets.2.4. Physical characterization of solid dispersion
2.4.1. Differential scanning calorimetry (DSC)
The DSC patterns were carried out using a Thermal Anacyzer-
60WS, Differential Scanning Calorimeter-60 (Shimadzu,
Japan). A sample of 10 mg was placed in perforated aluminum
pans and scanned through a temperature range of 30e180 C
at a heating rate of 10 C/min. The samples were pure NMD,
HPMCAS, SD, the physical mixture of NMD and HPMCAS.
2.4.2. Powder X-ray diffraction (PXRD)
PXRD was performed to evaluate the physical character of
NMD in the samples using an XRD2 micro-diffractometer
(BRUKER-D8 DISCOVER, Germany). The patterns were recor-
ded on a quartz plate at a tube voltage of 56 kV and a current ofTable 1 e Formulations of SD containing NMD.
Formulation no. NMD:carrier Type of carrier
SD0 1:3 HPMCAS-LF
SD1 1:3 HPMCAS-LG
SD2 1:3 HPMCAS-MF
SD3 1:3 HPMCAS-MG
SD4 1:3 HPMCAS-HF
SD5 1:3 HPMCAS-HG
SD6 1:5 HPMCAS-LF:HP-55 ¼ 3:2
SD7 1:1 HPMCAS-LF
SD8 1:2 HPMCAS-LF
SD9 1:3 HPMCAS-LF
SD10 1:4 HPMCAS-LF
SD11 1:5 HPMCAS-LF182 mA applying a scan rate of 2/min in the angular range of
0e1802q.2.5. Dissolution studies
The release profiles of solid dispersion and delayed-release
tablets were assessed using in vitro dissolution devices.
Dissolution studies were conducted according to USP34eNF29
apparatus 2 (paddle method) at 37 C  0.5 C and 100 rpm.
Appropriate amount of SD, physical mixture or the pure drug
were precisely weighted. Furthermore, the dissolution tests of
NMD-SD were respectively performed in pH 1.2 and pH 6.8
media for 2 h. A 5 ml sample was withdrawn at 0.5, 1 and 2 h
from the 900 ml pH 1.2 media. In the pH 6.8 buffer solution, a
5ml samplewas taken from the 900ml dissolutionmedia at 5,
15, 25, 35, 45, 60 and 120 min. For the delayed-release tablets,
the dissolution studies were performed under sink condition
by adding 0.5% sodium dodecyl sulfate (SDS) into the disso-
lutionmedia. The dissolutionmedia were 750ml pH 1.2media
(2.0 g NaCl, 7.0ml HCL andH2O) for the first 2 h, followed by pH
6.8 phosphate buffer solution (addition of 250 ml of 0.2 M so-
dium triphosphate buffer) for the next 12 h. A 5ml samplewas
withdrawn for every 2 h and each sample was passed through
0.45 mmfilter, and the drug content of it was determined by UV
spectrophotometer at 238 nm for SD or 356 nm for tablets.
Also a 5ml freshmediumwas added after each sampling. The
cumulative percentages of the drug dissolved from the SD and
the delayed-release tabletswere calculated (n¼ 3,mean SD).3. Results and discussion
3.1. Physical characterization of solid dispersion
In this part, results of DSC and PXRD were adopted to identify
the physical state of the drug in SD and its physical mixture.
Among the NMD-SD formulations, SD8 and its physical
mixture were tested, also the pure NMD and the excipient
HPMCAS were studied.
3.1.1. Powder X-ray diffraction (PXRD)
The results of PXRD were shown in Fig. 1. For pure drug and
corresponding physical mixture of SD8, a lot of diffraction
rings which represented information of NMD crystalline
diffraction peaks were detected in partial region. However, no
obvious rings were observed in SD8 pattern and HPMCAS
pattern at the corresponding position, i.e. no crystalline NMD
was detected [11]. Comparing Fig. 1a and c, difference could be
found that Fig. 1c still showed the same diffraction rings as
Fig. 1 e Powder X-ray diffraction (PXRD) diagrams. From
top to bottom: (1) pure NMD; (2) HPMCAS-LF; (3) physical
mixture of NMD and HPMCAS-LF (1:2); (4) SD8
.
Fig. 2 e Differential scanning calorimetry (DSC)
thermograms. (a) NMD; (b) HPMCAS-LF; (c) SD8; (d) physical
mixture of NMD and HPMCAS-LF.
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Fig. 1a. So it indicated that the crystalline form of NMD still
existed in the physical mixture. In addition, Fig. 1d had no
diffraction ring. The difference between Fig. 1a and d revealed
that the drug was in an amorphous state in SD8.
3.1.2. Differential scanning calorimetry (DSC)
The limit of detection is determined to be 2% for PXRD
method. It is commonly known that small sized crystals may
be not detected by PXRD even if their concentrations in the
sample are above the limit of detection [12]. For this reason,
DSC was applied as a second method to detect crystals. The
DSC patterns of samples with temperature ranging from 30 to
180 C were shown in Fig. 2. The pure NMD exhibited a sharp
endothermic peak around 126 C due to themelt of crystalline
drug and no similar peak was observed in DSC pattern of
HPMCAS. Physical mixture showed a relatively weak endo-
thermic peak at 124.7 C, while no peak was observed in the
SD8. So, it meant that the physical mixture didn’t have thesame characteristic as the SD. The difference between them
was due to the fusion and stir, it revealed that some interac-
tion had happened between the drug and the carrier in the SD.
Compared with the pure NMD and the physical mixture, the
DSC result of Fig. 2c indicated that the drug in SDwas possibly
converted into amorphous status which could increase the
dissolution rate and improve solubility, in agreement with the
PXRD observations.3.2. Dissolution studies
3.2.1. Dissolution results of nimodipine solid dispersion
(NMD-SD)
NMD was a poorly water-soluble drug with an equilibrium
solubility of 3.86 mg/ml in purified water. In this part, we
selected 900 ml pH 1.2 and 900 ml pH 6.8 solution as dissolu-
tion media without any surface active agent as solubilizer. So
this investigation was performed under non-sink condition.
Under non-sink condition, SD might lead to a temporary su-
persaturation in the dissolution media. Therefore, non-sink
condition was a better differentiation of SD formulations
and comparison of the degree of supersaturation reached
which depended upon dissolution of the powder and the
ability of the enteric polymer to inhibit precipitation of
NMD [12].
Comparing the 6 kinds of solid dispersions using different
types of HPMCAS with each other, it showed that all of the
solid dispersions dissolved not more than 10% in pH 1.2
dissolution media in 2 h (Fig. 3A). Moreover, the dissolution
rate and the cumulative percent drug released (%) of the
enteric solid dispersions were lower than the pure drug, the
characteristic was dominated by the carrier which did not
dissolve at pH 1.2. However, there were differences among the
six kinds of solid dispersions, if we considered the less the
drug released from the enteric SD in pH 1.2 dissolution media,
the better the carrier was.We could conclude from Fig. 3A: the
order of the type was HPMCAS-HF > HPMCAS-MG > HPMCAS-
MF > HPMCAS-HG > HPMCAS-LF > HPMCAS-LG.
Fig. 3 e The dissolution profiles of solid dispersions using different types of HPMCAS as carrier in pH 1.2 (A) and pH 6.8 (B)
dissolution media for 2 h (n [ 3, mean ± SD).
Fig. 4 e The dissolution profiles of solid dispersions using
HPMCAS as single carrier and HPMCAS/HP-55 as combined
carriers in pH 6.8 dissolution media for 2 h (n [ 3,
mean ± SD).
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tion behavior of enteric solid dispersions with different types
of HPMCAS in pH 6.8 solution. An increase in cumulative
percent drug released (%) was observed as the enteric polymer
dissolved and released the amorphous NMD within the poly-
mer leading to the maximum extent of released for all solid
dispersions. The sample (SD0) with HPMCAS-LF had the fast-
est dissolution rate, the most NMD (76.6%) released and su-
perior stability during 120 min. In another word, the curve
prompted that HPMCAS-LF was the most fitting carrier for
NMD in this experiment. The reason may be the fusion tem-
perature of SD0 during preparation was 126 C which was the
closest to NMD melt point (123 C), it might result in better
interaction between NMD and the carrier.
To investigate whether the combined carriers were supe-
rior to the single carrier in improving dissolution of poorly
water-soluble drug by adopting SD method, we chose HP-55
and HPMCAS as the combined carriers and HPMCAS as the
single carrier. The dissolution curve was listed in Fig. 4. Single
carrier had shown excellent effect in increasing dissolution
rate and maximum amount of drug released while the com-
bined carriers had not inhibited the precipitation of NMD
completely during 60e120 min.
Then we selected HPMCAS-LF as carrier to prepare SD with
theHPMCAS-LF/NMD ratio ranging from1 to 5. The dissolution
profiles were displayed in Fig. 5. In pH 1.2 media, the enteric
solid dispersion released much less than the pure drug due to
the pH dependence of carrier.With theHPMCAS-LF/NMD ratio
increasing, the cumulative percent drug released (%) became
lower and lower, however, the distinctions among the enteric
solid dispersionswerenot obvious (Fig. 5A).When thepHvalue
of dissolution media reached 6.8, the maximum amount of
drug released was observed (Fig. 5B). The highest cumulative
percentage of the drug dissolved from the preparations was
81.7% (SD11, NMD:HPMCAS-LF¼ 1:5), the minimum result was
57.9% (SD7, NMD:HPMCAS-LF ¼ 1:1), and there was no signifi-
cant difference among others (SD8, NMD:HPMCAS-LF ¼ 1:2;
SD9, NMD:HPMCAS-LF ¼ 1:3; SD10, NMD:HPMCAS-LF ¼ 1:4) of
which themaximumcumulative percentagewas about 80%. In
view of the amount of carrier used in the preparation and themaximum cumulative percentage of drug released, we chose
SD8 as the most superior SD formulation.
To judge whether the carrier or the SD technology
contributed to the enhancement of solubility and dissolution
rate, we compared the differences among NMD, SD8 and
physical mixture of NMD and HPMCAS-LF. It could be found
that, in pH 6.8 dissolution media, the cumulative percent drug
released (%) of SD8 was 2.2 times that of physical mixture and
the dissolution rate of SD8 was much more fast than that of
physical mixture, moreover, the dissolution behavior of
physical mixture was a little better than that of the pure drug.
The results indicated that the carrier accelerated the disso-
lution of NMD fromphysicalmixture in a certain degree, and it
also demonstrated that the SD technology was necessary in
improving the solubility and increasing the dissolution rate
(Fig. 6). The mechanism of SD was that it was a method which
could affect both specific surface area and solubility. The
release rate of the resultant formulation was greatly affected
Fig. 5 e The dissolution profiles of solid dispersions with different ratio of carriers in pH 1.2 (A) and pH 6.8 (B) dissolution
media for 2 h (n [ 3, mean ± SD).
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defined by the solubility of the drug in the polymer, the
method of preparation, the use of excipients, etc [10].
3.2.2. The release profiles for tablets comprising NMD solid
dispersion
We expected that the tablets released less than 10% in the
artificial gastric acid in the initial 2 h and release 20e35%, not
less than 75%,more than 90% at 4 h, 10 h and 14 h respectively
in the artificial intestinal fluid. The release curves of tablets
containing enteric solid dispersion were tested under sink
condition by adding 0.5% sodium dodecyl sulfate (SDS) into0 20 40 60 80 100 120
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Fig. 6 e The dissolution profiles of solid dispersion,
physical mixture and the pure drug. (A) SD8 in pH 6.8
dissolution media; (B) physical mixture of SD8 in pH 6.8
dissolution media; (C) NMD in pH 6.8 dissolution media; (D)
SD8 in pH 1.2 dissolutionmedia; (E) physical mixture of SD8
in pH 1.2 dissolution media; (F) NMD in pH 1.2 dissolution
media (n [ 3, mean ± SD).the dissolution media, the dissolution media were 750 ml pH
1.2 media (2.0 g NaCl, 7.0 ml HCL and H2O) for the first 2 h
followed by pH 6.8 phosphate buffer solution (addition of
250 ml of 0.2 M sodium triphosphate buffer) for the following
12 h, the results were given in Fig. 7. In Table 2, for formulation
1 and 5, the release rate was too fast during 2w4 h and the
phenomenon indicated that the amount of MCC might be a
little higher. Formulation 2 and 4 showed excessively low
dissolution rate because of the use of Kollidon SR or
Eudragit RS PO. Foumulation 3 released 2.4% in the artificial
gastric acid in the initial 2 h and released 32.1%, 75%, 91% at
4 h, 10 h and 14 h respectively in the artificial intestinal fluid.
According to the demand, Formulation 3 was the most supe-
rior one among the five formulations in Table 2.
There were many mathematical models for drug release/
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Fig. 7 e The release profiles of NMD delayed-release tablets
(Table 2) in 750 ml pH 1.2 media for the first 2 h followed by
pH 6.8 PBS for the following 12 h (n [ 3, mean ± SD).
Table 3 e Fitted equations of NMD delayed-release
tablets.
Models Equation Correlation
coefficient
Zero order Mt=MN ¼ 0:07004tþ 0:14807 r ¼ 0.9631
First order ln ð1Mt=MNÞ ¼ 0:17354t 0:02448 r ¼ 0.9984
Higuchi Mt=MN ¼ 0:26187t0:5  0:00479 r ¼ 0.9966
t: time, Mt=MN: cumulative percent drug released (%).
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order, first order, Higuchi equation to imitate the drug release
curves of formulation 3 in pH 6.8 dissolutionmedia. Zero order
model followed the characteristic that pharmaceutical dosage
forms released the same amount of drug by unit of time and it
was the ideal release method of drug release in order to ach-
ieve a pharmacological prolonged action. For first ordermodel,
the drug released from pharmaceutical dosage forms in a way
that was proportional to the amount of drug remaining in its
interior, it meant that the amount of drug released by unit of
time diminish. In this way, a graphic of the decimal logarithm
of the released amount of drug versus time would be linear
[13]. Higuchi equation described drug release as a diffusion
process based in the Fick’s law, square root time dependent.
The fitting results about delayed-release tablet were listed in
Table 3. The in vitro release profiles were expressed most fitly
by first-order release equation (R ¼ 0.9984).
In order to discuss the drug release mechanism of formu-
lation 3, we imitated the drug release profile using Peppas
equation: Mt=MN ¼ ktn; Where Mt=MN was the cumulative
percent drug released (%) in time t, k was the release rate
constant, n was the characteristic parameter representing
release mechanism. Peppas equation could be used for anal-
ysis of dissolution of solid dosage forms in differently
geometrical shape under sink condition. For a tablet, when
n < 0.45, the mechanismwas Fickian diffusion; when n > 0.89,
it was matrix erosion; when 0.45 < n < 0.89, it was the com-
bination ofmatrix erosion and diffusion. The fitting result was
:Mt=MN ¼ 0:23081t0:55746 (r ¼ 0.9986); because of 0.45 < n < 0.89
(n ¼ 0.55746), the release mechanism of formulation 3 was not
only diffusion but also matrix erosion. Moreover, the domi-
nant release mechanism was diffusion. In the initial stage of
the dissolution test, the swelling material (such as PEO) in
tablets started to uptake water in the pH 1.2 buffer medium,
resulting in an expansion of the tablets volume. This variation
would decrease the density of the tablets, and a less viscous
gel was generated. As a consequence, there was a faster
release profile at the following 2 h in pH 6.8 buffer medium
mainly due to the releasemechanism of erosion, and then the
drug-delivering behavior was slowing down when diffusion
mechanism held the dominant position at the sequent time.4. Conclusion
The present study demonstrated the development of an NMD
delayed-release tablet formulation using SD. The dissolution
rate and solubility of NMD solid dispersions were improved
compared with the pure drug. DSC and PXRD were adopted in
this investigation to identify the physical state of the drug inSD and it proved that the crystalline NMD transformed into
the amorphous state after preparation. To evaluate the
delayed-release tablets, we conducted the in vitro release
study, the delayed-release tablets released less than 10% in
the artificial gastric acid in the initial 2 h and release 32.1%, not
less than 75%,more than 90% at 4 h, 10 h and 14 h respectively
in the artificial intestinal fluid. Moreover, the in vitro release
profiles were expressed most fitly by first-order release
equation (R ¼ 0.9984), the release mechanism of tablets was
not only diffusion but also matrix erosion, and the dominant
release mechanism was diffusion.
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